Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Numab Therapeutics AG currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. This activity is spread across 2 distinct examiners and multiple distinct art units, indicating a diverse prosecution landscape for the company's current applications. This distribution suggests that the company's patent interests cover different technical aspects of biotechnology, each requiring a unique approach based on the specific art unit's standards.
DONOGHUE, BRITTNEY ERIN is the busiest examiner for the portfolio with 1 busiest examiner pending action. Because the 2 pending actions are split between different examiners and art units, the company must navigate varying examination styles and unit-specific precedents simultaneously. This requires a more complex strategy than a centralized portfolio, as the applicant cannot rely on a single examiner's preferences to guide the entire prosecution effort.
The presence of multiple art units means that the company's Biotechnology & Pharmaceuticals filings are being scrutinized by different groups of experts. Practitioners must be diligent in tracking the separate timelines and requirements for each of the pending office actions. Successfully managing these diverse interactions with DONOGHUE, BRITTNEY ERIN and other examiners will be essential for Numab Therapeutics AG to secure its intellectual property rights across the different technical domains.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DONOGHUE, BRITTNEY ERIN | 1 | 58.8% | +46.5% |
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258939 | ANTIBODY VARIABLE DOMAINS THAT BIND IL-4R | DONOGHUE, BRITTNEY ERIN | — |
| 18258957 | ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY | MELCHIOR, JAMES RYLAND | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258939 | ANTIBODY VARIABLE DOMAINS THAT BIND IL-4R | DONOGHUE, BRITTNEY ERIN | 1675 | §112DP | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18258957 | ANTIBODY VARIABLE DOMAINS AND ANTIBODIES HAVING DECREASED IMMUNOGENICITY | MELCHIOR, JAMES RYLAND | 1644 | §112DPOther | Non-Final OA | — | Pending | Jun 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial